This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an editorially independent information service, is a scheduled system of the Kaiser Family Foundation, a nonpartisan health care policy research firm unaffiliated with Kaiser Permanente.. A.U. Pledges $46M for Horn of Africa; USAID official discusses U.S. Response At a gathering of the African Union in Ethiopia, ‘African governments. The amount fell brief of the $50 million asked for by the help group Africans Act 4 Africa, the newspaper provides, noting that ‘the African Advancement Bank announced a $300 million donation for long-term advancement in the Horn of Africa’ .4 billion shortfall aid groups say they need for the crisis’ ., , a late-stage drug development company specific in endocrine and oncology therapy, today announced a collaborative study with Almac’s Diagnostics division for the business’s doxorubicin luteinizing hormone-releasing hormone targeted conjugate substance, AEZS-108, aimed at identifying LHRH receptor expression through the development of a companion diagnostic tool. Selection for treatment with AEZS-108 is set based on LHRH receptor expression, currently measured immunohistochemically. In humans, LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate and pancreatic tumors. AEZS-108 is currently in Phase 2 trials for advanced LHRH receptor positive ovarian and endometrial cancer tumor.